Clinical Trials Browser

Phase 2/3 × Carcinoma, Renal Cell × Clear all

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05770037 2025-11-24

DETERMINE

CNSGenitourinaryLymphoidOther hematologic neoplasm

Carcinoma, Renal Cell, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neuroblastoma, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

NCT02883153 2017-06-19

Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma

Phase 2/3 Completed

30 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT02829775 2017-01-09

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Phase 2/3 Completed

9 enrolled 7 charts

DermatologicGenitourinaryMyeloidOther hematologic neoplasm

Carcinoma, Renal Cell, Melanoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00420888 2015-07-22

ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma

Phase 2/3 Completed

526 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT02030717 2015-06-04

ASA

Phase 2/3 Completed

120 enrolled

Genitourinary

Carcinoma, Renal Cell

Clinical Trials

HARRIER

DETERMINE

Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma

ASA